[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371225-105":59,"doc-detail-371225-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","igf2bp3-is-upregulated-in-endometrial-cancer-and-tightly-regulates-the-growth-of-drug-resistant-endometrial-cancer-cells-via-hmga1","IGF2BP3 is upregulated in endometrial cancer and tightly regulates the growth of drug-resistant endometrial cancer cells via HMGA1","","Endometrial cancer (EC) is a malignant disease with diverse histological subtypes and molecular phenotypes, and drug resistance limits effective treatment. Progesterone resistance is a major challenge, and understanding resistance mechanisms is crucial for developing new therapies. This study quantified IGF2BP3 and HMGA1 in paracancerous and tumor tissues, then used AN3CA and Ishikawa cells to assess functional roles. IGF2BP3 and HMGA1 were elevated in EC tissues and cisplatin-resistant cells, and IGF2BP3 knockdown reduced cisplatin-resistant growth via HMGA1. The results support IGF2BP3/HMGA1 as targets for novel EC treatments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/igf2bp3-is-upregulated-in-endometrial-cancer-and-tightly-regulates-the-growth-of-drug-resistant-endometrial-cancer-cells-via-hmga1/371225/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/igf2bp3-is-upregulated-in-endometrial-cancer-and-tightly-regulates-the-growth-of-drug-resistant-endometrial-cancer-cells-via-hmga1/371225.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this study on endometrial cancer?","Question",{"text":112,"@type":113},"To determine whether IGF2BP3 is upregulated in endometrial cancer and whether it regulates the growth of drug-resistant endometrial cancer cells through HMGA1.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were IGF2BP3 and HMGA1 measured in the study?",{"text":117,"@type":113},"Ten paracancerous and ten tumor tissues were collected, and IGF2BP3 mRNA binding protein 3 and HMGA1 were measured. Cell models (AN3CA and Ishikawa) were used to study functional effects.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the key findings regarding cisplatin-resistant EC cells?",{"text":121,"@type":113},"IGF2BP3 and HMGA1 were higher in EC tumor tissues than in paracancerous tissues and were highly expressed in cisplatin-resistant EC cells. Knockdown of IGF2BP3 reduced the growth of cisplatin-resistant cells and decreased HMGA1 protein, while HMGA1 knockdown also reduced growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371225,1790217899,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Original Research Article SCIENCE PROGRESS  \nIGF2BP3 is upregulated in endometrial cancer and tightly regulates the growth of drugresistant endometrial cancer cells via HMGA1  \nYiwei Zhang 1,*, Yanlai Xiao 1, Xiangzhai Zhao 1, Jie Xu 1, Huan Zhao 1, Zhaojun Guo 1, Jun Zhao 1, Yajing Zhang 1, Ruoxi Wang 1 and Jian Wang 1,*  1 Department of Obstetrics and Gynecology, Hebei Medical University Third Hospital, Shijiazhuang, China  \nScience Progress 2025, Vol. 108(1) 1–17 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/00368504251315008](DOI: 10.1177/00368504251315008)[ ](DOI: 10.1177/00368504251315008)[journals.sagepub.com/home/sci](journals.sagepub.com/home/sci)  \nAbstract  \nObjective: Endometrial cancer (EC) is a malignant tumor with various histological subtypes and molecular phenotypes. The evaluation of drug resistance is important for cancer treatment. Progesterone resistance is the major challenge in EC. Knowledge of drug resistance in EC is important in the development of novel therapies.  \nMethods: In this study, ten paracancerous and ten tumor tissues were collected to measure the expression of insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) and high-mobility group protein 1 (HMGA1). AN3CA and Ishikawa cells were used to explore the effects of IGF2BP3 on EC.  \nResults: The expression levels of IGF2BP3 and HMGA1 were higher in EC tumor tissues than in paracancerous tissues. IGF2BP3 and HMGA1 are highly expressed in cisplatin-resistant EC cells. IGF2BP3 knockdown decreased the growth of cisplatin-resistant EC cells. Knockdown of IGF2BP3 decreased the level of HMGA1 protein. HMGA1 knockdown decreased the growth ofcisplatin-resistant EC cells.  \nDiscuss and conclusions: The ﬁndings demonstrate that IGF2BP3 is upregulated in EC and closely regulates the growth of drug-resistant EC cells via HMGA1. The ﬁndings will inform the development of novel therapies for EC.  \n*Contributed equally.  \nCorresponding author:  \nJian Wang, Department of Obstetrics and Gynecology, Hebei Medical University Third Hospital, 139 Ziqiang Road, Shijiazhuang 050051, Hebei, China.  \nEmail: [37100746@hebmu.edu.cn](37100746@hebmu.edu.cn)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative  \nCommons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access page ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nKeywords  \nIGF2BP3, endometrial cancer, drug resistance, HMGA1  \nIntroduction  \nEndometrial cancer (EC) is a malignant tumor with various histological subtypes and molecular phenotypes.1 EC is one of the main diseases that burden public health, affecting an estimated 142,000 women worldwide each year, with approximately 42,000 women dying annually due to EC.1 The 5-year overall survival rate of patients with EC is approximately 80% at all stages.1 The global incidence of EC continues to increase.2 Although most patients are diagnosed at an early stage, the 5-year survival rate is quite low.2 In the United States, the population with EC is doubling annually.3  \nEC comprises types I and II,4 caused by multiple factors, and they often involve excessive unopposed exposure of the endometrium to estrogen, including unopposed estrogen therapy, early menarche, late menopause, tamoxifen therapy, nulliparity, infertility or failure to ovulate, polycystic ovary syndrome, and others.4 EC is induced by germline mutations, with Lynch syndrome displaying one of the strongest associations.4 Postmenopausal bleeding is a common characteristic of EC.4 Nonsurgical","cbCaiohY22iH13Sy","https://ap.wps.com/l/cbCaiohY22iH13Sy","pdf",4103395,17,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Discuss and conclusions\n# Introduction","[{\"question\":\"What is the main objective of this study on endometrial cancer?\",\"answer\":\"To determine whether IGF2BP3 is upregulated in endometrial cancer and whether it regulates the growth of drug-resistant endometrial cancer cells through HMGA1.\"},{\"question\":\"How were IGF2BP3 and HMGA1 measured in the study?\",\"answer\":\"Ten paracancerous and ten tumor tissues were collected, and IGF2BP3 mRNA binding protein 3 and HMGA1 were measured. Cell models (AN3CA and Ishikawa) were used to study functional effects.\"},{\"question\":\"What are the key findings regarding cisplatin-resistant EC cells?\",\"answer\":\"IGF2BP3 and HMGA1 were higher in EC tumor tissues than in paracancerous tissues and were highly expressed in cisplatin-resistant EC cells. Knockdown of IGF2BP3 reduced the growth of cisplatin-resistant cells and decreased HMGA1 protein, while HMGA1 knockdown also reduced growth.\"}]","IGF2BP3 is upregulated in endometrial cancer and tightly regulates the growth of drug-resistant endometrial cancer cells via HMGA1 | PDF",1790191564,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ce993fa25953149bffb9293da2ae5c0.webp",983,1415,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0c4d6c5e2bf17f4c9b4ca4760a28db2.webp",982,1414,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41db932dabf9437cf2e109d85ea1c4bb.webp",981,1412,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8028083e1907efac1f7b742e8a0157ad.webp",980,1411]